Want to see SE:IBT.B full AI Analyst Report?
Top Page
Infant Bacterial Therapeutics AB
(IBT.B)
Select Model
Select Model
Rating:54Neutral
Price Target:
kr73.00
▲(15.87% Upside)
Action:Reiterated
Date:09/22/26
The score is primarily constrained by weak financial performance (no revenue, ongoing losses, and continued cash burn), despite the benefit of a debt-free balance sheet. Technicals are a meaningful positive, with the stock trading above major moving averages and positive momentum indicators. Valuation is a modest headwind because the company is loss-making (negative P/E) and there is no dividend yield support.
Positive Factors
Debt-free balance sheet
A debt-free capital structure reduces interest obligations and refinancing exposure while preserving flexibility during clinical development. This gives IBT more room to direct available capital toward its pipeline and limits the financial stress that leverage could impose before commercialization.
Negative Factors
No recurring product revenue
The absence of revenue means IBT currently lacks an operating income base to fund research, clinical trials, or corporate costs. Until a candidate is approved, partnered, or commercialized, financial performance remains dependent on capital access and successful future development outcomes.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free capital structure reduces interest obligations and refinancing exposure while preserving flexibility during clinical development. This gives IBT more room to direct available capital toward its pipeline and limits the financial stress that leverage could impose before commercialization.
Read all positive factors
Infant Bacterial Therapeutics AB (IBT.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr941.65M
Dividend YieldN/A
Average Volume (3M)9.94K
Price to Earnings (P/E)―
Beta (1Y)-0.40
Revenue GrowthN/A
EPS Growth19.94%
CountrySE
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.09
Shares Outstanding13,018,137
10 Day Avg. Volume6,540
30 Day Avg. Volume9,944
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)6.46
Price to Sales (P/S)0.00
P/FCF Ratio-9.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-6.72
Revenue Forecast (FY)N/A
Infant Bacterial Therapeutics AB Business Overview & Revenue Model
Company Description
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which...
How the Company Makes Money
Infant Bacterial Therapeutics AB is a clinical-stage biotechnology company and, based on publicly available information, it has not been characterized as generating material recurring revenue from product sales. Its primary economic model is to in...
Infant Bacterial Therapeutics AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 4.00K | 77.00K | 12.00K | 0.00 |
| Gross Profit | 0.00 | 0.00 | 4.00K | 77.00K | 12.00K | 0.00 |
| EBITDA | -82.02M | -68.18M | -136.91M | 11.55M | -64.34M | -43.76M |
| Net Income | -81.92M | -65.17M | -136.91M | -123.07M | -65.45M | -44.99M |
Balance Sheet | ||||||
| Total Assets | 120.22M | 161.75M | 239.57M | 351.33M | 349.62M | 408.48M |
| Cash, Cash Equivalents and Short-Term Investments | 108.60M | 144.01M | 223.39M | 329.06M | 335.84M | 386.75M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 67.20M | 56.42M | 69.30M | 46.18M | 17.91M | 13.22M |
| Stockholders Equity | 53.02M | 105.33M | 170.26M | 305.15M | 331.71M | 395.25M |
Cash Flow | ||||||
| Free Cash Flow | -64.06M | -72.34M | -113.13M | -101.22M | -85.80M | -55.62M |
| Operating Cash Flow | -64.06M | -72.34M | -113.13M | -101.22M | -85.80M | -55.62M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -4.15M | -1.00K | 0.00 |
| Financing Cash Flow | 0.00 | 0.00 | 2.01M | 96.52M | 1.88M | 91.00K |
Infant Bacterial Therapeutics AB Technical Analysis
Positive
63.00
Price Trends
66.01
Positive
63.97
Positive
57.47
Positive
Market Momentum
1.16
Negative
58.17
Neutral
49.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IBT.B, the sentiment is Positive. The current price of 63 is below the 20-day moving average (MA) of 66.69, below the 50-day MA of 66.01, and above the 200-day MA of 57.47, indicating a bullish trend. The MACD of 1.16 indicates Negative momentum. The RSI at 58.17 is Neutral, neither overbought nor oversold. The STOCH value of 49.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:IBT.B.
Infant Bacterial Therapeutics AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | kr3.47B | -4.22 | ― | ― | -3.57% | 8.84% | |
54 Neutral | kr941.65M | -11.41 | -89.70% | ― | ― | 19.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr217.39M | -4.34 | -13.41% | ― | -68.66% | -137.27% | |
46 Neutral | kr351.04M | -3.67 | -34.25% | ― | -0.71% | 54.16% | |
43 Neutral | kr1.48B | -3.03 | -99.58% | ― | -87.22% | -70.29% | |
41 Neutral | kr27.93M | -0.16 | -104.71% | ― | -2.29% | 55.71% |
* Healthcare Sector Average
SE:IBT.B
Infant Bacterial Therapeutics AB
69.50
2.80
4.20%
SE:HNSA
Hansa Biopharma AB
33.18
-6.28
-15.91%
SE:BINV
BioInvent International AB
22.90
-5.10
-18.21%
SE:XBRANE
Xbrane Biopharma AB
10.40
-22.25
-68.15%
SE:IVACC
Intervacc AB
0.97
-0.06
-5.54%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
1.10
-6.50
-85.57%
Infant Bacterial Therapeutics AB Corporate Events
IBT Secures FDA Pre-BLA Meeting for Breakthrough Neonatal Therapy
Sep 21, 2026
Infant Bacterial Therapeutics AB, a Stockholm-based pharmaceutical company listed on Nasdaq Stockholm, specializes in therapies for premature infants, led by its live biotherapeutic candidate IBP-9414 derived from bacteria in human breast milk. Th...
Infant Bacterial Therapeutics Sets Nomination Committee Ahead of 2027 AGM
Sep 18, 2026
Infant Bacterial Therapeutics AB has appointed its Nomination Committee for the 2027 Annual General Meeting, in line with its established governance framework and based on the ownership structure as of June 30, 2026. The committee includes represe...
Infant Bacterial Therapeutics Advances IBP-9414 Toward Market Despite Wider Losses
Aug 26, 2026
Infant Bacterial Therapeutics AB reported no net sales for the first half of 2026 and a widened operating loss, reflecting its pre-commercial stage as it advances its lead neonatal drug candidate IBP-9414 toward market approval. Despite the financ...
Infant Bacterial Therapeutics Announces CFO Departure Amid Late-Stage Drug Push
Jul 7, 2026
Infant Bacterial Therapeutics AB announced that Chief Financial Officer Maria Ekdahl will leave the company on October 7, prompting the appointment of an external consultant to oversee the finance function during the search for a permanent success...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.